Financing ·
Raises A$5.5M via option exercises, holds A$41.3M cash as Phase 3 MSA trial prep advances
ATHEAlterity Therapeutics Ltd
Alterity Therapeutics raised approximately A$5.5 million through the exercise of listed options and received an A$3.98 million R&D tax refund, bringing its cash balance to A$41.3 million at September 30, 2026. The company confirmed alignment with the FDA on the Phase 3 trial design for ATH434 in Multiple System Atrophy (MSA) and began operational start-up activities, including vendor selection and site identification. Additionally, the USPTO granted a new composition of matter patent for ATH434 extending protection to 2045. Alterity Therapeutics is a clinical-stage biotechnology company developing disease-modifying therapies for neurodegenerative diseases.